Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical liposomal amphotericin B plus Glucantime for anthroponotic cutaneous leishmaniasis
IRCT201504211475N7Phase 3Completed
- Sponsor
- MoH, EMRO/WHO
- Start
- Oct 2015
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, single-arm trial of liposomal amphotericin b and meglumine antimoniate in cutaneous leishmaniasis (CL), sponsored by MoH, EMRO/WHO. Started Oct 2015; status: completed.
02
Drugs
liposomal amphotericin bmeglumine antimoniate
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on IRCT201504211475N7.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT201504211475N7.